A detailed history of Citigroup Inc transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 1,000,389 shares of EGRX stock, worth $650,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000,389
Previous 1,001,555 0.12%
Holding current value
$650,252
Previous $5.61 Million 33.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.71 - $6.07 $4,325 - $7,077
-1,166 Reduced 0.12%
1,000,389 $3.71 Million
Q2 2024

Aug 12, 2024

BUY
$3.34 - $5.6 $3.34 Million - $5.59 Million
998,837 Added 36748.97%
1,001,555 $5.61 Million
Q1 2024

May 10, 2024

BUY
$4.26 - $6.51 $4,140 - $6,327
972 Added 55.67%
2,718 $14,000
Q4 2023

Feb 09, 2024

BUY
$4.63 - $15.21 $7,144 - $23,469
1,543 Added 760.1%
1,746 $9,000
Q3 2023

Nov 09, 2023

SELL
$15.21 - $22.88 $88,735 - $133,481
-5,834 Reduced 96.64%
203 $3,000
Q2 2023

Aug 10, 2023

SELL
$17.74 - $31.87 $24,392 - $43,821
-1,375 Reduced 18.55%
6,037 $117,000
Q1 2023

May 11, 2023

SELL
$25.06 - $34.09 $660,731 - $898,816
-26,366 Reduced 78.06%
7,412 $210,000
Q4 2022

Feb 09, 2023

SELL
$24.98 - $39.77 $614,832 - $978,859
-24,613 Reduced 42.15%
33,778 $987,000
Q3 2022

Nov 10, 2022

BUY
$26.42 - $47.12 $822,005 - $1.47 Million
31,113 Added 114.06%
58,391 $1.54 Million
Q2 2022

Aug 10, 2022

BUY
$41.26 - $51.35 $460,956 - $573,682
11,172 Added 69.37%
27,278 $1.21 Million
Q1 2022

May 12, 2022

SELL
$44.58 - $52.6 $877,780 - $1.04 Million
-19,690 Reduced 55.01%
16,106 $797,000
Q4 2021

Feb 10, 2022

BUY
$45.82 - $56.9 $666,176 - $827,269
14,539 Added 68.4%
35,796 $1.82 Million
Q3 2021

Nov 10, 2021

BUY
$43.79 - $55.78 $930,844 - $1.19 Million
21,257 New
21,257 $1.19 Million

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $8.46M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.